Sorafenib - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (10)Enzymes (11)Transporters (5)

Targets (10)Enzymes (11)Transporters (5)Biointeractions (32)

Identification

Name

Sorafenib

Accession Number

DB00398 (APRD01304, DB07438)

Type

Small Molecule

Groups

Approved, Investigational

Description

Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide

N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea

Sorafenibum

External IDs

BAY 43-9006 / BAY-43-9006

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Sorafenib Tosylate	5T62Q3B36J	475207-59-1	IVDHYUQIDRJSTI-UHFFFAOYSA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Nexavar	Tablet, film coated	200 mg/1	Oral	Bayer	2005-12-20	Not applicable	US
Nexavar	Tablet	200 mg	Oral	Bayer	2006-07-31	Not applicable	Canada
Nexavar	Tablet, film coated	200 mg	Oral	Bayer Pharma Ag	2006-07-19	Not applicable	EU

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

9ZOQ3TZI87

CAS number

284461-73-0

Weight

Average: 464.825
Monoisotopic: 464.08630272

Chemical Formula

C₂₁H₁₆ClF₃N₄O₃

InChI Key

MLDQJTXFUGDVEO-UHFFFAOYSA-N

InChI

InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

IUPAC Name

4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide

SMILES

CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1

Pharmacology

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

Structured Indications

Pharmacodynamics

No large changes in QTc interval were observed. After one 28-day treatment cycle, the largest mean QTc interval change of 8.5 ms (upper bound of two-sided 90% confidence interval, 13.3 ms) was observed at 6 hours post-dose on day 1 of cycle 2.

Mechanism of action

Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Serine/threonine-protein kinase B-raf	Protein	yes	inhibitor	Human	P15056	details
RAF proto-oncogene serine/threonine-protein kinase	Protein	yes	inhibitor	Human	P04049	details
Vascular endothelial growth factor receptor 3	Protein	yes	antagonist	Human	P35916	details
Vascular endothelial growth factor receptor 2	Protein	yes	antagonist	Human	P35968	details
Receptor-type tyrosine-protein kinase FLT3	Protein	yes	antagonist	Human	P36888	details
Platelet-derived growth factor receptor beta	Protein	yes	antagonist	Human	P09619	details
Mast/stem cell growth factor receptor Kit	Protein	yes	antagonist	Human	P10721	details
Fibroblast growth factor receptor 1	Protein	yes	inhibitor	Human	P11362	details
Proto-oncogene tyrosine-protein kinase receptor Ret	Protein	yes	inhibitor	Human	P07949	details
Vascular endothelial growth factor receptor 1	Protein	yes	inhibitor	Human	P17948	details

Absorption

The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma levels in 3 hours following oral administration. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.

Volume of distribution

Not Available

Protein binding

99.5% bound to plasma proteins.

Metabolism

Sorafenib is metabolized primarily in the liver, undergoing oxidative metabolism, mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9. Sorafenib accounts for approximately 70-85% of the circulating analytes in plasma at steady- state. Eight metabolites of sorafenib have been identified, of which five have been detected in plasma. The main circulating metabolite of sorafenib in plasma, the pyridine N-oxide, shows in vitro potency similar to that of sorafenib. This metabolite comprises approximately 9-16% of circulating analytes at steady-state.

Substrate	Enzymes	Product
Sorafenib	Cytochrome P450 3A4	Pyridine N-oxide	Details
Sorafenib	Not Available	Pyridine N-oxide glucuronide	Details
Sorafenib	UDP-glucuronosyltransferase 1-9	Sorafenib beta-D-Glucuronide	Details

Route of elimination

Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of the dose excreted in urine as glucuronidated metabolites.

Half life

25-48 hours

Clearance

Not Available

Toxicity

The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Sorafenib Metabolism Pathway	Drug metabolism	SMP00648

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Abiraterone	The serum concentration of Sorafenib can be increased when it is combined with Abiraterone.	Approved
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Sorafenib.	Approved
Aceclofenac	The metabolism of Aceclofenac can be decreased when combined with Sorafenib.	Approved
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Sorafenib.	Approved
Acetaminophen	Acetaminophen may increase the hepatotoxic activities of Sorafenib.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Sorafenib.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Sorafenib.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Sorafenib.	Approved
Albendazole	The serum concentration of Sorafenib can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Sorafenib can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Sorafenib can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Sorafenib can be increased when it is combined with Alfentanil.	Approved, Illicit
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Sorafenib.	Approved, Investigational
Alosetron	The metabolism of Alosetron can be decreased when combined with Sorafenib.	Approved, Withdrawn
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Sorafenib.	Approved, Illicit, Investigational
Amantadine	The serum concentration of Sorafenib can be increased when it is combined with Amantadine.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Sorafenib.	Approved, Investigational
Aminohippuric acid	The serum concentration of Sorafenib can be increased when it is combined with Aminohippuric acid.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Sorafenib.	Approved, Withdrawn
Amiodarone	The serum concentration of Sorafenib can be increased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Sorafenib can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Sorafenib can be increased when it is combined with Amlodipine.	Approved
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Sorafenib.	Approved
Amprenavir	The serum concentration of Sorafenib can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Sorafenib can be increased when it is combined with Amsacrine.	Approved
Anagrelide	Sorafenib may increase the QTc-prolonging activities of Anagrelide.	Approved
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Sorafenib.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Sorafenib.	Approved
Aprepitant	The serum concentration of Sorafenib can be increased when it is combined with Aprepitant.	Approved, Investigational
Arachidonic Acid	The metabolism of Arachidonic Acid can be decreased when combined with Sorafenib.	Experimental
Arformoterol	The metabolism of Arformoterol can be decreased when combined with Sorafenib.	Approved, Investigational
Arsenic trioxide	Sorafenib may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Sorafenib may increase the QTc-prolonging activities of Artemether.	Approved
Asenapine	Sorafenib may increase the QTc-prolonging activities of Asenapine.	Approved
Astemizole	The serum concentration of Sorafenib can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Sorafenib can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Sorafenib can be increased when it is combined with Atenolol.	Approved
Atomoxetine	The metabolism of Sorafenib can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Sorafenib can be increased when it is combined with Atorvastatin.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Sorafenib.	Approved, Investigational
Azelastine	The serum concentration of Sorafenib can be increased when it is combined with Azelastine.	Approved
Azithromycin	Sorafenib may increase the QTc-prolonging activities of Azithromycin.	Approved
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Sorafenib.	Investigational
BCG vaccine	The therapeutic efficacy of Bcg can be decreased when used in combination with Sorafenib.	Investigational
Bedaquiline	Sorafenib may increase the QTc-prolonging activities of Bedaquiline.	Approved
Benzocaine	The serum concentration of Sorafenib can be increased when it is combined with Benzocaine.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Sorafenib.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Sorafenib.	Approved
Bepridil	The serum concentration of Sorafenib can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Sorafenib.	Approved, Vet Approved
Bevacizumab	The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.	Approved, Investigational
Bexarotene	The serum concentration of Sorafenib can be decreased when it is combined with Bexarotene.	Approved, Investigational
Biperiden	The serum concentration of Sorafenib can be increased when it is combined with Biperiden.	Approved
Boceprevir	The serum concentration of Sorafenib can be increased when it is combined with Boceprevir.	Approved, Investigational
Bortezomib	The metabolism of Sorafenib can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be increased when it is combined with Sorafenib.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Sorafenib.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib.	Approved
Bromocriptine	The serum concentration of Sorafenib can be increased when it is combined with Bromocriptine.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Sorafenib.	Approved
Buprenorphine	The serum concentration of Sorafenib can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The serum concentration of Bupropion can be increased when it is combined with Sorafenib.	Approved
Buspirone	The serum concentration of Sorafenib can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sorafenib.	Approved
Cabozantinib	The metabolism of Cabozantinib can be decreased when combined with Sorafenib.	Approved
Caffeine	The serum concentration of Sorafenib can be increased when it is combined with Caffeine.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Sorafenib.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.	Approved
Candesartan	The serum concentration of Sorafenib can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Sorafenib can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Sorafenib can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Sorafenib.	Approved
Carboplatin	The risk or severity of adverse effects can be increased when Sorafenib is combined with Carboplatin.	Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Sorafenib.	Approved
Carvedilol	The serum concentration of Carvedilol can be increased when it is combined with Sorafenib.	Approved, Investigational
Caspofungin	The serum concentration of Sorafenib can be increased when it is combined with Caspofungin.	Approved
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Sorafenib.	Approved, Investigational
Ceritinib	The serum concentration of Sorafenib can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Sorafenib.	Withdrawn
Chloroquine	Sorafenib may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorpromazine	Sorafenib may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Sorafenib can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Sorafenib can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The serum concentration of Sorafenib can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Sorafenib can be decreased when it is combined with Cholic Acid.	Approved
Cilazapril	The serum concentration of Sorafenib can be increased when it is combined with Cilazapril.	Approved
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Sorafenib.	Approved
Cimetidine	The serum concentration of Sorafenib can be decreased when it is combined with Cimetidine.	Approved
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Sorafenib.	Approved
Ciprofloxacin	Sorafenib may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Sorafenib may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Sorafenib.	Approved
Citalopram	Sorafenib may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	The serum concentration of Sorafenib can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The metabolism of Sorafenib can be decreased when combined with Clemastine.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Sorafenib.	Approved, Illicit
Clofazimine	The serum concentration of Sorafenib can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Sorafenib.	Approved, Investigational
Clomipramine	The serum concentration of Sorafenib can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clonidine	The serum concentration of Clonidine can be increased when it is combined with Sorafenib.	Approved
Clopidogrel	The metabolism of Sorafenib can be decreased when combined with Clopidogrel.	Approved, Nutraceutical
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Sorafenib.	Approved, Illicit
Clotrimazole	The metabolism of Sorafenib can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Sorafenib is combined with Clozapine.	Approved
Cobicistat	The serum concentration of Sorafenib can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Sorafenib.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Sorafenib.	Approved
Colforsin	The serum concentration of Sorafenib can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Sorafenib can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sorafenib.	Approved
Crizotinib	Sorafenib may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Sorafenib.	Approved, Investigational
Cyclosporine	The metabolism of Sorafenib can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sorafenib.	Approved
Dabrafenib	The serum concentration of Sorafenib can be decreased when it is combined with Dabrafenib.	Approved
Dacarbazine	The serum concentration of Dacarbazine can be decreased when it is combined with Sorafenib.	Approved, Investigational
Daclatasvir	The serum concentration of Sorafenib can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Sorafenib can be increased when it is combined with Dactinomycin.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be increased when it is combined with Sorafenib.	Approved
Dapsone	The metabolism of Dapsone can be decreased when combined with Sorafenib.	Approved, Investigational
Darunavir	The serum concentration of Sorafenib can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Sorafenib can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Sorafenib can be decreased when it is combined with Daunorubicin.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Sorafenib.	Approved
Deferasirox	The serum concentration of Sorafenib can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Sorafenib can be decreased when combined with Delavirdine.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Sorafenib.	Approved
Desipramine	The serum concentration of Sorafenib can be increased when it is combined with Desipramine.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Sorafenib.	Approved
Desloratadine	The serum concentration of Sorafenib can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Sorafenib can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of Sorafenib can be increased when it is combined with Dextromethorphan.	Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Sorafenib.	Approved, Illicit, Vet Approved
Diclofenac	The serum concentration of Sorafenib can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dicoumarol	The metabolism of Dicoumarol can be decreased when combined with Sorafenib.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Sorafenib.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Sorafenib.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Sorafenib.	Approved
Dihydroergotamine	The metabolism of Sorafenib can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Sorafenib.	Illicit
Diltiazem	The metabolism of Sorafenib can be decreased when combined with Diltiazem.	Approved
Diphenhydramine	The metabolism of Diphenhydramine can be decreased when combined with Sorafenib.	Approved
Dipyridamole	The serum concentration of Sorafenib can be increased when it is combined with Dipyridamole.	Approved
Disopyramide	Sorafenib may increase the QTc-prolonging activities of Disopyramide.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Sorafenib.	Approved, Investigational
Dofetilide	Sorafenib may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Sorafenib may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Sorafenib may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Sorafenib.	Approved
Dopamine	The metabolism of Dopamine can be decreased when combined with Sorafenib.	Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Sorafenib.	Approved
Doxazosin	The serum concentration of Sorafenib can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Sorafenib can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Sorafenib.	Approved, Investigational
Doxorubicin	The serum concentration of Sorafenib can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Doxycycline	The metabolism of Sorafenib can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Sorafenib.	Approved, Illicit
Dronedarone	Sorafenib may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Sorafenib may increase the QTc-prolonging activities of Droperidol.	Approved, Vet Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Sorafenib.	Approved
Efavirenz	The serum concentration of Sorafenib can be decreased when it is combined with Efavirenz.	Approved, Investigational
Elbasvir	The serum concentration of Sorafenib can be increased when it is combined with Elbasvir.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Sorafenib.	Approved, Investigational
Eliglustat	Sorafenib may increase the QTc-prolonging activities of Eliglustat.	Approved
Eltrombopag	The serum concentration of Sorafenib can be increased when it is combined with Eltrombopag.	Approved
Enalapril	The serum concentration of Sorafenib can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Sorafenib can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Sorafenib.	Approved, Investigational
Epoprostenol	The metabolism of Epoprostenol can be decreased when combined with Sorafenib.	Approved
Ergonovine	The serum concentration of Sorafenib can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Sorafenib can be increased when it is combined with Ergotamine.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Sorafenib.	Approved, Investigational
Erythromycin	Sorafenib may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	Sorafenib may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Sorafenib can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Sorafenib.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Sorafenib can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Sorafenib can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Sorafenib can be decreased when it is combined with Estrone.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Sorafenib.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Sorafenib.	Approved
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Sorafenib.	Approved, Illicit
Etodolac	The metabolism of Etodolac can be decreased when combined with Sorafenib.	Approved, Investigational, Vet Approved
Etoposide	The serum concentration of Sorafenib can be increased when it is combined with Etoposide.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Sorafenib.	Approved, Investigational
Etravirine	The serum concentration of Sorafenib can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Sorafenib.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Sorafenib.	Approved
Felodipine	The serum concentration of Sorafenib can be increased when it is combined with Felodipine.	Approved, Investigational
Fentanyl	The serum concentration of Sorafenib can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.	Approved
Fexofenadine	The serum concentration of Sorafenib can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Sorafenib.	Approved
Fingolimod	Sorafenib may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Flecainide	Sorafenib may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Fluconazole	The metabolism of Sorafenib can be decreased when combined with Fluconazole.	Approved
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Sorafenib.	Approved
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Sorafenib.	Approved, Illicit
Fluorouracil	The serum concentration of Fluorouracil can be decreased when it is combined with Sorafenib.	Approved
Fluoxetine	Sorafenib may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	Sorafenib may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Sorafenib can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Sorafenib can be increased when it is combined with Flurazepam.	Approved, Illicit
Flurbiprofen	The metabolism of Flurbiprofen can be decreased when combined with Sorafenib.	Approved, Investigational
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Sorafenib.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Sorafenib.	Approved
Fluvoxamine	The metabolism of Sorafenib can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formoterol	The metabolism of Formoterol can be decreased when combined with Sorafenib.	Approved, Investigational
Fosamprenavir	The metabolism of Sorafenib can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Sorafenib can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Sorafenib can be decreased when it is combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Sorafenib can be increased when it is combined with Fusidic Acid.	Approved
G17DT	The risk or severity of adverse effects can be increased when Sorafenib is combined with G17DT.	Investigational
Gadobenic acid	Sorafenib may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Gavestinel	The metabolism of Gavestinel can be decreased when combined with Sorafenib.	Investigational
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Sorafenib.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Sorafenib.	Approved
Gemfibrozil	The metabolism of Sorafenib can be decreased when combined with Gemfibrozil.	Approved
Gemifloxacin	Sorafenib may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Sorafenib can be increased when it is combined with Genistein.	Investigational
Gliclazide	The metabolism of Gliclazide can be decreased when combined with Sorafenib.	Approved
Glimepiride	The metabolism of Glimepiride can be decreased when combined with Sorafenib.	Approved
Glipizide	The metabolism of Glipizide can be decreased when combined with Sorafenib.	Approved
Glyburide	The serum concentration of Sorafenib can be increased when it is combined with Glyburide.	Approved
Goserelin	Sorafenib may increase the QTc-prolonging activities of Goserelin.	Approved
Gramicidin D	The serum concentration of Sorafenib can be increased when it is combined with Gramicidin D.	Approved
Granisetron	Sorafenib may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Sorafenib.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Sorafenib.	Withdrawn
Guanfacine	The metabolism of Guanfacine can be decreased when combined with Sorafenib.	Approved, Investigational
Haloperidol	Sorafenib may increase the QTc-prolonging activities of Haloperidol.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Sorafenib.	Approved, Vet Approved
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Sorafenib.	Approved
Histamine	The metabolism of Histamine Phosphate can be decreased when combined with Sorafenib.	Approved, Investigational
Hydrocortisone	The serum concentration of Sorafenib can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Sorafenib.	Approved, Illicit
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Sorafenib.	Approved
Ibutilide	Sorafenib may increase the QTc-prolonging activities of Ibutilide.	Approved
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Sorafenib.	Approved
Idelalisib	The serum concentration of Sorafenib can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Sorafenib.	Approved
Iloperidone	Sorafenib may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The metabolism of Sorafenib can be decreased when combined with Imatinib.	Approved
Imipramine	The serum concentration of Sorafenib can be increased when it is combined with Imipramine.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Sorafenib.	Approved
Indinavir	The serum concentration of Sorafenib can be increased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Sorafenib can be increased when it is combined with Indomethacin.	Approved, Investigational
INGN 201	The risk or severity of adverse effects can be increased when Sorafenib is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Sorafenib is combined with INGN 225.	Investigational
Irbesartan	The metabolism of Irbesartan can be decreased when combined with Sorafenib.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Sorafenib.	Approved, Investigational
Isavuconazonium	The metabolism of Sorafenib can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoflurane	The metabolism of Isoflurane can be decreased when combined with Sorafenib.	Approved, Vet Approved
Isradipine	The metabolism of Sorafenib can be decreased when combined with Isradipine.	Approved
Itraconazole	The serum concentration of Sorafenib can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Sorafenib can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Sorafenib can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Sorafenib.	Approved
Ketamine	The serum concentration of Sorafenib can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Sorafenib.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Sorafenib.	Approved
Ketoconazole	The serum concentration of Sorafenib can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The metabolism of Ketoprofen can be decreased when combined with Sorafenib.	Approved, Vet Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Sorafenib.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Sorafenib.	Approved, Investigational
Lansoprazole	The serum concentration of Sorafenib can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Sorafenib can be increased when it is combined with Lapatinib.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Sorafenib.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Sorafenib is combined with Leflunomide.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Sorafenib.	Approved
Lenvatinib	Sorafenib may increase the QTc-prolonging activities of Lenvatinib.	Approved
Lesinurad	The metabolism of Lesinurad can be decreased when combined with Sorafenib.	Approved
Leuprolide	Sorafenib may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Sorafenib.	Approved, Investigational
Levofloxacin	Sorafenib may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Sorafenib.	Approved
Levothyroxine	The serum concentration of Sorafenib can be decreased when it is combined with Levothyroxine.	Approved
Licofelone	The metabolism of Licofelone can be decreased when combined with Sorafenib.	Investigational
Lidocaine	The serum concentration of Sorafenib can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Sorafenib.	Approved
Liothyronine	The serum concentration of Sorafenib can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Sorafenib can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Sorafenib can be increased when it is combined with Lisinopril.	Approved, Investigational
Lomitapide	The serum concentration of Sorafenib can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Sorafenib can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Sorafenib can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Sorafenib can be increased when it is combined with Loratadine.	Approved
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Sorafenib.	Approved
Lornoxicam	The metabolism of Lornoxicam can be decreased when combined with Sorafenib.	Approved
Losartan	The serum concentration of Sorafenib can be increased when it is combined with Losartan.	Approved
Lovastatin	The metabolism of Sorafenib can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Sorafenib can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Sorafenib can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	Sorafenib may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lumiracoxib	The metabolism of Lumiracoxib can be decreased when combined with Sorafenib.	Approved, Investigational
Malathion	The metabolism of Malathion can be decreased when combined with Sorafenib.	Approved, Investigational
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Sorafenib.	Approved, Investigational
Maprotiline	The serum concentration of Sorafenib can be increased when it is combined with Maprotiline.	Approved
Mebendazole	The serum concentration of Sorafenib can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Sorafenib.	Approved
Mefloquine	The serum concentration of Sorafenib can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Sorafenib can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Melatonin	The metabolism of Melatonin can be decreased when combined with Sorafenib.	Approved, Nutraceutical, Vet Approved
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Sorafenib.	Approved, Vet Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Sorafenib.	Investigational, Withdrawn
Meprobamate	The serum concentration of Sorafenib can be increased when it is combined with Meprobamate.	Approved, Illicit
Mestranol	The metabolism of Mestranol can be decreased when combined with Sorafenib.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Sorafenib.	Withdrawn
Methadone	Sorafenib may increase the QTc-prolonging activities of Methadone.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Sorafenib.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Sorafenib.	Approved, Vet Approved
Methylphenobarbital	The metabolism of Methylphenobarbital can be decreased when combined with Sorafenib.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Sorafenib.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Sorafenib.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Sorafenib.	Approved, Investigational
Metronidazole	The metabolism of Metronidazole can be decreased when combined with Sorafenib.	Approved
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Sorafenib.	Approved
Mianserin	The metabolism of Mianserin can be decreased when combined with Sorafenib.	Approved
Mibefradil	The serum concentration of Sorafenib can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Sorafenib can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Sorafenib can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Sorafenib can be increased when it is combined with Mifepristone.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Sorafenib.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Sorafenib.	Approved
Mitomycin	The serum concentration of Sorafenib can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Sorafenib can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Sorafenib can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Sorafenib.	Approved
Modafinil	The serum concentration of Sorafenib can be decreased when it is combined with Modafinil.	Approved, Investigational
Montelukast	The metabolism of Montelukast can be decreased when combined with Sorafenib.	Approved
Morphine	The serum concentration of Sorafenib can be increased when it is combined with Morphine.	Approved, Investigational
Moxifloxacin	Sorafenib may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Sorafenib.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Sorafenib.	Approved
Nafcillin	The serum concentration of Sorafenib can be decreased when it is combined with Nafcillin.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Sorafenib.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Sorafenib.	Approved, Vet Approved
Naltrexone	The serum concentration of Sorafenib can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naproxen	The metabolism of Naproxen can be decreased when combined with Sorafenib.	Approved, Vet Approved
Naringenin	The serum concentration of Sorafenib can be increased when it is combined with Naringenin.	Experimental
Natalizumab	The risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.	Approved, Investigational
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Sorafenib.	Approved, Investigational
Nefazodone	The serum concentration of Sorafenib can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Sorafenib can be increased when it is combined with Nelfinavir.	Approved
Neomycin	The serum concentration of Sorafenib can be decreased when it is combined with Neomycin.	Approved, Vet Approved
Neostigmine	The serum concentration of Sorafenib can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Sorafenib can be increased when it is combined with Netupitant.	Approved
Nevirapine	The serum concentration of Sorafenib can be decreased when it is combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Sorafenib can be increased when it is combined with Nicardipine.	Approved
Niclosamide	The metabolism of Niclosamide can be decreased when combined with Sorafenib.	Approved, Vet Approved
Nicotine	The metabolism of Nicotine can be decreased when combined with Sorafenib.	Approved
Nifedipine	The serum concentration of Sorafenib can be decreased when it is combined with Nifedipine.	Approved
Nilotinib	Sorafenib may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Sorafenib.	Approved
Nisoldipine	The serum concentration of Sorafenib can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Sorafenib can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Sorafenib can be increased when it is combined with Nitrendipine.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Sorafenib.	Approved
Norethisterone	The serum concentration of Sorafenib can be decreased when it is combined with Norethisterone.	Approved
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Sorafenib.	Approved
Ofloxacin	Sorafenib may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Sorafenib.	Approved, Investigational
Olaparib	The metabolism of Sorafenib can be decreased when combined with Olaparib.	Approved
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Sorafenib.	Experimental
Olodaterol	The metabolism of Olodaterol can be decreased when combined with Sorafenib.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Sorafenib.	Approved
Omeprazole	The serum concentration of Sorafenib can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	Sorafenib may increase the QTc-prolonging activities of Ondansetron.	Approved
Osimertinib	The serum concentration of Sorafenib can be increased when it is combined with Osimertinib.	Approved
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Sorafenib.	Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Sorafenib.	Approved
Oxaprozin	The metabolism of Oxaprozin can be decreased when combined with Sorafenib.	Approved
P-Nitrophenol	The serum concentration of Sorafenib can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.	Approved, Vet Approved
Palbociclib	The serum concentration of Sorafenib can be increased when it is combined with Palbociclib.	Approved
Paliperidone	Sorafenib may increase the QTc-prolonging activities of Paliperidone.	Approved
Palmitic Acid	The serum concentration of Sorafenib can be increased when it is combined with Palmitic Acid.	Experimental
Panobinostat	Sorafenib may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Pantoprazole	The serum concentration of Sorafenib can be increased when it is combined with Pantoprazole.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Sorafenib.	Approved
Parecoxib	The metabolism of Parecoxib can be decreased when combined with Sorafenib.	Approved
Paroxetine	The serum concentration of Sorafenib can be increased when it is combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Sorafenib.	Approved
Pentamidine	Sorafenib may increase the QTc-prolonging activities of Pentamidine.	Approved
Pentobarbital	The serum concentration of Sorafenib can be decreased when it is combined with Pentobarbital.	Approved, Vet Approved
Perflutren	Sorafenib may increase the QTc-prolonging activities of Perflutren.	Approved
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Sorafenib.	Approved
Perindopril	The serum concentration of Sorafenib can be increased when it is combined with Perindopril.	Approved
Permethrin	The metabolism of Permethrin can be decreased when combined with Sorafenib.	Approved, Investigational
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Sorafenib.	Approved
Pethidine	The metabolism of Pethidine can be decreased when combined with Sorafenib.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Sorafenib.	Withdrawn
Phenobarbital	The serum concentration of Sorafenib can be decreased when it is combined with Phenobarbital.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Sorafenib.	Approved
Phenylbutazone	The metabolism of Phenylbutazone can be decreased when combined with Sorafenib.	Approved, Vet Approved
Phenytoin	The serum concentration of Sorafenib can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sorafenib.	Approved, Investigational
Pimozide	Sorafenib may increase the QTc-prolonging activities of Pimozide.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Sorafenib.	Approved, Investigational
Piroxicam	The metabolism of Piroxicam can be decreased when combined with Sorafenib.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Sorafenib.	Approved
Platelet Activating Factor	The serum concentration of Sorafenib can be decreased when it is combined with Platelet Activating Factor.	Experimental
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Sorafenib.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Sorafenib.	Approved
Posaconazole	The serum concentration of Sorafenib can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Prasugrel	The metabolism of Prasugrel can be decreased when combined with Sorafenib.	Approved
Pravastatin	The serum concentration of Sorafenib can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Sorafenib can be increased when it is combined with Prazosin.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Sorafenib.	Approved, Vet Approved
Prednisone	The serum concentration of Sorafenib can be increased when it is combined with Prednisone.	Approved, Vet Approved
Primaquine	Sorafenib may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The serum concentration of Sorafenib can be decreased when it is combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Sorafenib can be increased when it is combined with Probenecid.	Approved
Procainamide	Sorafenib may increase the QTc-prolonging activities of Procainamide.	Approved
Progesterone	The serum concentration of Sorafenib can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Sorafenib.	Approved
Promazine	Sorafenib may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Promethazine	The serum concentration of Sorafenib can be increased when it is combined with Promethazine.	Approved
Propacetamol	Sorafenib may increase the hepatotoxic activities of Propacetamol.	Approved
Propafenone	Sorafenib may increase the QTc-prolonging activities of Propafenone.	Approved
Propofol	The metabolism of Propofol can be decreased when combined with Sorafenib.	Approved, Investigational, Vet Approved
Propranolol	The serum concentration of Sorafenib can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Sorafenib can be increased when it is combined with Protriptyline.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Sorafenib.	Approved
Quazepam	The serum concentration of Sorafenib can be increased when it is combined with Quazepam.	Approved, Illicit
Quercetin	The serum concentration of Sorafenib can be increased when it is combined with Quercetin.	Experimental
Quetiapine	Sorafenib may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinacrine	The serum concentration of Sorafenib can be increased when it is combined with Quinacrine.	Approved
Quinidine	Sorafenib may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Sorafenib may increase the QTc-prolonging activities of Quinine.	Approved
Rabeprazole	The metabolism of Sorafenib can be decreased when combined with Rabeprazole.	Approved, Investigational
Ranitidine	The serum concentration of Sorafenib can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Sorafenib.	Approved, Investigational
Reboxetine	The serum concentration of Sorafenib can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Sorafenib can be increased when it is combined with Regorafenib.	Approved
Reserpine	The serum concentration of Sorafenib can be decreased when it is combined with Reserpine.	Approved
Rifabutin	The serum concentration of Sorafenib can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Sorafenib can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Sorafenib can be decreased when it is combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Sorafenib.	Approved, Investigational
Rilpivirine	The serum concentration of Sorafenib can be increased when it is combined with Rilpivirine.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when Sorafenib is combined with CDX-110.	Investigational
Risperidone	The serum concentration of Risperidone can be increased when it is combined with Sorafenib.	Approved, Investigational
Ritonavir	The serum concentration of Sorafenib can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Sorafenib.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Sorafenib.	Investigational, Withdrawn
Roflumilast	Roflumilast may increase the immunosuppressive activities of Sorafenib.	Approved
Rolapitant	The serum concentration of Sorafenib can be increased when it is combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Sorafenib.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Sorafenib.	Approved
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Sorafenib.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Sorafenib.	Approved
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Sorafenib.	Approved, Vet Approved
Saquinavir	The serum concentration of Sorafenib can be increased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Sorafenib can be increased when it is combined with Scopolamine.	Approved
Secobarbital	The metabolism of Sorafenib can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	The serum concentration of Sorafenib can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Sorafenib.	Approved
Sertraline	The serum concentration of Sorafenib can be increased when it is combined with Sertraline.	Approved
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Sorafenib.	Approved, Vet Approved
Sildenafil	The metabolism of Sorafenib can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Sorafenib.	Approved
Siltuximab	The serum concentration of Sorafenib can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Sorafenib can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Sorafenib can be increased when it is combined with Simvastatin.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sorafenib.	Approved
Sirolimus	The serum concentration of Sorafenib can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Sorafenib.	Approved, Investigational
Sitaxentan	The metabolism of Sitaxentan can be decreased when combined with Sorafenib.	Approved, Investigational, Withdrawn
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Sorafenib.	Approved
Sotalol	Sorafenib may increase the QTc-prolonging activities of Sotalol.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Sorafenib.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Sorafenib.	Experimental
Spironolactone	The serum concentration of Sorafenib can be increased when it is combined with Spironolactone.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Sorafenib is combined with SRP 299.	Investigational
St. John's Wort	The serum concentration of Sorafenib can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Sorafenib can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Sorafenib can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Sorafenib can be decreased when it is combined with Streptozocin.	Approved
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Sorafenib.	Approved, Vet Approved
Sulfamethoxazole	The metabolism of Sulfamethoxazole can be decreased when combined with Sorafenib.	Approved
Sulfamoxole	The metabolism of Sulfamoxole can be decreased when combined with Sorafenib.	Approved
Sulfinpyrazone	The serum concentration of Sorafenib can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	Sorafenib may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sumatriptan	The serum concentration of Sorafenib can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Sorafenib can be increased when it is combined with Sunitinib.	Approved, Investigational
Suprofen	The metabolism of Suprofen can be decreased when combined with Sorafenib.	Approved, Withdrawn
Tacrine	The serum concentration of Sorafenib can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sorafenib.	Approved, Investigational
Tacrolimus	The serum concentration of Sorafenib can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Sorafenib can be decreased when it is combined with Tamoxifen.	Approved
Tapentadol	The metabolism of Tapentadol can be decreased when combined with Sorafenib.	Approved
Taurocholic Acid	The serum concentration of Sorafenib can be increased when it is combined with Taurocholic Acid.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Sorafenib.	Approved
Telaprevir	The serum concentration of Sorafenib can be increased when it is combined with Telaprevir.	Withdrawn
Telavancin	Sorafenib may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	The serum concentration of Sorafenib can be increased when it is combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Sorafenib can be increased when it is combined with Telmisartan.	Approved, Investigational
Temazepam	The metabolism of Temazepam can be decreased when combined with Sorafenib.	Approved
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Sorafenib.	Approved
Tenoxicam	The metabolism of Tenoxicam can be decreased when combined with Sorafenib.	Approved
Terazosin	The serum concentration of Sorafenib can be increased when it is combined with Terazosin.	Approved
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Sorafenib.	Approved, Investigational, Vet Approved
Terfenadine	The serum concentration of Sorafenib can be increased when it is combined with Terfenadine.	Withdrawn
Teriflunomide	The serum concentration of Sorafenib can be increased when it is combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Sorafenib can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Sorafenib can be increased when it is combined with Testosterone.	Approved, Investigational
Tetrabenazine	Sorafenib may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Thalidomide	The metabolism of Thalidomide can be decreased when combined with Sorafenib.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Theophylline can be decreased when combined with Sorafenib.	Approved
Thiamylal	The metabolism of Thiamylal can be decreased when combined with Sorafenib.	Approved, Vet Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Sorafenib.	Withdrawn
Thiotepa	The metabolism of Sorafenib can be decreased when combined with Thiotepa.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Sorafenib.	Approved
Ticlopidine	The metabolism of Sorafenib can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be increased when it is combined with Sorafenib.	Approved
Tocilizumab	The serum concentration of Sorafenib can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Sorafenib may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Sorafenib.	Approved
Tolterodine	The metabolism of Tolterodine can be decreased when combined with Sorafenib.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Sorafenib.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Sorafenib.	Approved, Investigational
Torasemide	The metabolism of Torasemide can be decreased when combined with Sorafenib.	Approved
Toremifene	Sorafenib may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Sorafenib.	Approved, Investigational
Tramadol	The metabolism of Tramadol can be decreased when combined with Sorafenib.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Sorafenib.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Sorafenib.	Approved
Trazodone	The serum concentration of Sorafenib can be decreased when it is combined with Trazodone.	Approved, Investigational
Treprostinil	The metabolism of Treprostinil can be decreased when combined with Sorafenib.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Sorafenib.	Approved, Investigational, Nutraceutical
Trifluoperazine	The serum concentration of Sorafenib can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Sorafenib can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Sorafenib.	Approved
Trimethoprim	The serum concentration of Sorafenib can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Sorafenib can be increased when it is combined with Trimipramine.	Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Sorafenib.	Withdrawn
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Sorafenib.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Sorafenib.	Approved
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Sorafenib.	Investigational, Withdrawn
Valproic Acid	The metabolism of Valproic Acid can be decreased when combined with Sorafenib.	Approved, Investigational
Valsartan	The metabolism of Valsartan can be decreased when combined with Sorafenib.	Approved, Investigational
Vandetanib	Sorafenib may increase the QTc-prolonging activities of Vandetanib.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Sorafenib.	Approved
Vemurafenib	Sorafenib may increase the QTc-prolonging activities of Vemurafenib.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Sorafenib.	Approved
Venlafaxine	The metabolism of Sorafenib can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Sorafenib can be decreased when combined with Verapamil.	Approved
Vinblastine	The serum concentration of Sorafenib can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Sorafenib.	Approved, Investigational
Vincristine	The serum concentration of Sorafenib can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Sorafenib can be increased when it is combined with Vinorelbine.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Sorafenib.	Approved
Voriconazole	The serum concentration of Sorafenib can be increased when it is combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Sorafenib.	Approved
Warfarin	Sorafenib may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	The metabolism of Ximelagatran can be decreased when combined with Sorafenib.	Approved, Investigational, Withdrawn
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Sorafenib.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Sorafenib.	Approved
Zaltoprofen	The metabolism of Zaltoprofen can be decreased when combined with Sorafenib.	Approved
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Sorafenib.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Sorafenib.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Sorafenib can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	Sorafenib may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Sorafenib.	Approved
Zopiclone	The metabolism of Zopiclone can be decreased when combined with Sorafenib.	Approved
Zuclopenthixol	Sorafenib may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Ales Gavenda, Alexandr Jegorov, Pierluigi Rossetto, Peter Lindsay MacDonald, Augusto Canavesi, "POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF." U.S. Patent US20090192200, issued July 30, 2009.

US20090192200

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14542
KEGG Drug	D08524
PubChem Compound	216239
PubChem Substance	46505329
ChemSpider	187440
BindingDB	16673
ChEBI	50924
ChEMBL	CHEMBL1336
Therapeutic Targets Database	DAP000006
PharmGKB	PA7000
HET	BAX
Drug Product Database	15231
RxList	http://www.rxlist.com/nexavar-drug.htm
Drugs.com	http://www.drugs.com/cdi/sorafenib.html
Wikipedia	Sorafenib

ATC Codes

L01XE05 — Sorafenib

AHFS Codes

92:00.00

PDB Entries

Not Available

FDA label

Download (310 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Treatment	Renal Cancers	1
0	Terminated	Treatment	Hepatocellular,Carcinoma	1
1	Active Not Recruiting	Treatment	Acute Myeloid Leukaemias (AML)	1
1	Active Not Recruiting	Treatment	Adult Primary Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / BCLC Stage B Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma	1
1	Active Not Recruiting	Treatment	Adult Solid Neoplasm / Advanced Malignant Solid Neoplasm / Recurrent Melanoma / Refractory Malignant Solid Neoplasm / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma / Stages III Skin Melanoma	1
1	Active Not Recruiting	Treatment	Cancer, Advanced	2
1	Active Not Recruiting	Treatment	Cancer, Advanced / Tumors, Solid	1
1	Active Not Recruiting	Treatment	Hepatocellular Cancer / Liver Cancer	1
1	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma	3
1	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma / Malignant Neoplasm of Pancreas	1
1	Active Not Recruiting	Treatment	Liver Cancer	2
1	Active Not Recruiting	Treatment	Metastatic Renal Cell Carcinoma	1
1	Active Not Recruiting	Treatment	Non Small Cell Lung Carcinoma (NSCLC)	1
1	Active Not Recruiting	Treatment	Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia	1
1	Active Not Recruiting	Treatment	Sarcomas	1
1	Active Not Recruiting	Treatment	Tumors Metastatic to Brain	1
1	Active Not Recruiting	Treatment	Tumors, Solid	1
1	Completed	Not Available	Advanced Solid Tumors / Refractory to Standard Therapies	1
1	Completed	Not Available	Drug Interactions	1
1	Completed	Not Available	Neoplasms	1
1	Completed	Basic Science	Kidney Diseases	1
1	Completed	Basic Science	Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Completed	Health Services Research	Fasting	1
1	Completed	Other	Biological Availability	1
1	Completed	Treatment	Acute Myelogenous Leukaemia (AML) / Leukemias	1
1	Completed	Treatment	Acute Myeloid Leukaemias (AML)	1
1	Completed	Treatment	Acute Myeloid Leukaemias (AML) / Biphenotypic Leukemia / Infantile Leukemia (Both AML and ALL) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms	1
1	Completed	Treatment	Acute Promyelocytic Leukemia (APL) / Leukemia, Myeloid, Acute / Myelodysplastic Syndromes	1
1	Completed	Treatment	Adenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas	1
1	Completed	Treatment	Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia	1
1	Completed	Treatment	Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Blastic Phase / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes	1
1	Completed	Treatment	Adult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor	1
1	Completed	Treatment	Adult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma	1
1	Completed	Treatment	Adult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Resectable Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer	1
1	Completed	Treatment	Advanced Cancers	1
1	Completed	Treatment	Advanced Malignant Neoplasm	1
1	Completed	Treatment	Advanced Solid Tumors	3
1	Completed	Treatment	Advanced Solid Tumors / Malignant Lymphomas	1
1	Completed	Treatment	Bladder Cancers	1
1	Completed	Treatment	Cancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Prostate / Mesothelioma / Sarcomas	1
1	Completed	Treatment	Cancers	2
1	Completed	Treatment	Carcinoid Tumors / Neuroendocrine Tumors / Progressive Neuroendocrine Tumors of pancreatic origin	1
1	Completed	Treatment	Carcinoma NOS	1
1	Completed	Treatment	Carcinoma, Small Cell / Lung Cancers	1
1	Completed	Treatment	Ewing's Sarcoma Family of Tumors / Neoplasms, Brain / Neuroblastomas / Rhabdomyosarcoma and Other Soft Tissue Sarcomas / Sarcoma, Osteogenic	1
1	Completed	Treatment	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)	1
1	Completed	Treatment	Gastrointestinal Tumors / Metastatic Breast Cancer (MBC)	1
1	Completed	Treatment	Glioblastomas / Gliosarcoma	1
1	Completed	Treatment	HHV-8 / Kaposi s Sarcoma (KS) / KSHV	1
1	Completed	Treatment	Hepatocellular Cancer	1
1	Completed	Treatment	Hepatocellular,Carcinoma	9
1	Completed	Treatment	Hepatocellular,Carcinoma / Liver Cancer / Localized Unresectable Liver Cancer	1
1	Completed	Treatment	Leukemias / Refractory Solid Tumors	1
1	Completed	Treatment	Leukemias / With AML and FLT3-ITD Mutations	1
1	Completed	Treatment	Liver Diseases	1
1	Completed	Treatment	Lung Cancers	1
1	Completed	Treatment	Malignant Neoplasm of Pancreas	1
1	Completed	Treatment	Malignant Neoplasm of Prostate	1
1	Completed	Treatment	Malignant Neoplasm of Prostate / Primary Disease	1
1	Completed	Treatment	Malignant Neoplasm of Stomach	1
1	Completed	Treatment	Malignant Solid Tumours / Non Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma	1
1	Completed	Treatment	Melanoma	1
1	Completed	Treatment	Melanoma (Skin)	1
1	Completed	Treatment	Melanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma	1
1	Completed	Treatment	Melanoma / Renal Cancers	1
1	Completed	Treatment	Metastatic Brain Tumors / Primary Brain Tumors	1
1	Completed	Treatment	Metastatic Colorectal Cancers	1
1	Completed	Treatment	Neoplasms	4
1	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC) / Relapsed and/or Refractory Solid Tumors / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Pulmonary Arterial Hypertension (PAH)	1
1	Completed	Treatment	Rectal Carcinoma	1
1	Completed	Treatment	Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer	1
1	Completed	Treatment	Recurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer	1
1	Completed	Treatment	Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Stage III Multiple Myeloma / Stage IV Chronic Lymphocytic Leukemia / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Refractory Malignancy	1
1	Completed	Treatment	Refractory Solid Tumors	1
1	Completed	Treatment	Renal Cancers / Tumors	1
1	Completed	Treatment	Renal Cell Adenocarcinoma	1
1	Completed	Treatment	T Cell Lymphomas	1
1	Completed	Treatment	Tumors, Solid	3
1	Completed	Treatment	Unresectable or Metastatic Hepatocellular Carcinoma (HCC)	1
1	Completed	Treatment	Unspecified Adult Solid Tumor	1
1	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	4
1	Not Yet Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Hematopoietic/Lymphoid Cancer	1
1	Recruiting	Treatment	Acute Myeloid Leukaemias (AML)	1
1	Recruiting	Treatment	Adenocarcinoma of the Pancreas / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer	1
1	Recruiting	Treatment	Advanced Cancers	1
1	Recruiting	Treatment	Advanced Solid Tumors / Hepatocellular,Carcinoma	1
1	Recruiting	Treatment	Bladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer	1
1	Recruiting	Treatment	Cancer, Breast / Metastatic Brain Tumors	1
1	Recruiting	Treatment	Hepatocellular Cancer / Liver Cancer	1
1	Recruiting	Treatment	Hepatocellular,Carcinoma	1
1	Recruiting	Treatment	Hepatocellular,Carcinoma / Liver Cancer / Unresectable Hepatocellular Carcinoma	1
1	Recruiting	Treatment	Neoplasms	1
1	Recruiting	Treatment	Neuroblastomas	2
1	Recruiting	Treatment	Ocular Melanoma	1
1	Recruiting	Treatment	Untreated Adult Acute Myeloid Leukemia	1
1	Suspended	Treatment	Recurrent Hepatocellular Carcinoma / Solid Neoplasms / Stage IV Hepatocellular Carcinoma	1
1	Terminated	Basic Science	Renal Cell Adenocarcinoma	1
1	Terminated	Treatment	Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Blastic Phase Chronic Myelogenous Leukemia / Recurrent Adult Acute Myeloid Leukemia / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Terminated	Treatment	Hepatocellular,Carcinoma	3
1	Terminated	Treatment	Liver Cancer	2
1	Terminated	Treatment	Lung Cancers	1
1	Terminated	Treatment	Metastatic Colorectal Cancers	1
1	Terminated	Treatment	Neoplasms	1
1	Terminated	Treatment	Renal Cancers	1
1	Terminated	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	1
1	Unknown Status	Treatment	Hepatocellular Cancer	1
1	Unknown Status	Treatment	Hepatocellular,Carcinoma	1
1	Unknown Status	Treatment	Metastatic or Locally Advanced Solid Tumors	1
1	Withdrawn	Not Available	Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)	1
1	Withdrawn	Treatment	Advanced Cancers	1
1	Withdrawn	Treatment	Hepatocellular Cancer / Hepatocellular,Carcinoma / Liver Cancer	1
1	Withdrawn	Treatment	Hepatocellular,Carcinoma	1
1, 2	Active Not Recruiting	Treatment	Adenoma, Liver Cell / Hepatocellular,Carcinoma / Liver Neoplasms, Experimental / Neoplasms, Hepatic	1
1, 2	Active Not Recruiting	Treatment	Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor	1
1, 2	Active Not Recruiting	Treatment	Cancers / Liver Metastasis	1
1, 2	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma	2
1, 2	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma / Liver Cancer	1
1, 2	Active Not Recruiting	Treatment	Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm	1
1, 2	Active Not Recruiting	Treatment	Metastatic Breast Cancer (MBC)	1
1, 2	Active Not Recruiting	Treatment	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary	1
1, 2	Active Not Recruiting	Treatment	Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
1, 2	Completed	Not Available	Renal Cell Adenocarcinoma	1
1, 2	Completed	Treatment	Acute Myeloid Leukaemias (AML) / AML / Myelodysplastic Disorders	1
1, 2	Completed	Treatment	Acinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1, 2	Completed	Treatment	Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor	1
1, 2	Completed	Treatment	Advanced Hepatocellular Carcinoma	1
1, 2	Completed	Treatment	Advanced Liver Cancer / Metastatic Hepatocellular Carcinoma	1
1, 2	Completed	Treatment	Bile Duct Neoplasms / Neoplasms, Pancreatic	1
1, 2	Completed	Treatment	Biliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer	1
1, 2	Completed	Treatment	Cancer of the Cervix	1
1, 2	Completed	Treatment	Cancer, Advanced	1
1, 2	Completed	Treatment	Cancer, Breast	1
1, 2	Completed	Treatment	Chromophobe Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Papillary Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Sarcomatoid Renal Cell Carcinoma / Stage IV Renal Cell Cancer	1
1, 2	Completed	Treatment	Colorectal Cancers	1
1, 2	Completed	Treatment	Gastric cancer stage IV	1
1, 2	Completed	Treatment	Hepatocellular,Carcinoma	3
1, 2	Completed	Treatment	Leukemias	1
1, 2	Completed	Treatment	Liver Cancer	1
1, 2	Completed	Treatment	Malignant Neoplasm of Prostate	1
1, 2	Completed	Treatment	Metastatic Breast Cancer (MBC)	1
1, 2	Completed	Treatment	Metastatic Colorectal Cancers	1
1, 2	Completed	Treatment	Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Recurrent Breast Cancer / Stage IV Breast Cancer	1
1, 2	Completed	Treatment	Renal Cancers	1
1, 2	Completed	Treatment	Renal Cell Adenocarcinoma	2
1, 2	Completed	Treatment	Soft Tissue Sarcoma (STS)	1
1, 2	Completed	Treatment	Squamous Cell Cancer	1
1, 2	Not Yet Recruiting	Treatment	Advanced Adult Hepatocellular Carcinoma / Child-Pugh Class A / Stage III Hepatocellular Carcinoma / Stage IIIA Hepatocellular Carcinoma / Stage IIIB Hepatocellular Carcinoma / Stage IIIC Hepatocellular Carcinoma / Stage IV Hepatocellular Carcinoma / Stage IVA Hepatocellular Carcinoma / Stage IVB Hepatocellular Carcinoma	1
1, 2	Recruiting	Treatment	Acute Biphenotypic Leukemia (ABL) / Acute Myeloid Leukaemias (AML) / De Novo Myelodysplastic Syndrome / Myeloproliferative Neoplasms	1
1, 2	Recruiting	Treatment	Acute Myeloid Leukaemias (AML)	1
1, 2	Recruiting	Treatment	Acute Myeloid Leukaemias (AML) / Leukemias	1
1, 2	Recruiting	Treatment	Anaplastic Gliomas / Glioblastomas / Neoplasms, Brain	1
1, 2	Recruiting	Treatment	HCC / Hepatocellular,Carcinoma / Liver Cancer	1
1, 2	Recruiting	Treatment	Hepatocellular,Carcinoma	4
1, 2	Suspended	Treatment	Advanced Solid Tumors	1
1, 2	Suspended	Treatment	Liver Cancer / Renal Cancers	1
1, 2	Terminated	Treatment	Cancer, Ovarian	1
1, 2	Terminated	Treatment	Hepatocellular,Carcinoma	3
1, 2	Terminated	Treatment	Lung Cancers	1
1, 2	Terminated	Treatment	Malignant Neoplasm of Prostate	1
1, 2	Terminated	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
1, 2	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
1, 2	Unknown Status	Treatment	Hepatocellular,Carcinoma	1
1, 2	Unknown Status	Treatment	Melanoma (Skin)	2
1, 2	Unknown Status	Treatment	Metastatic Breast Cancer (MBC)	1
1, 2	Unknown Status	Treatment	Soft Tissue Sarcoma (STS)	1
1, 2	Withdrawn	Treatment	Advanced Hepatocellular Carcinoma	1
1, 2	Withdrawn	Treatment	Hepatocellular,Carcinoma	1
2	Active Not Recruiting	Treatment	Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22)(p13;q13); RBM15-MKL1 / Acute Myeloid Leukemia With a Variant RARA Translocation / Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214 / Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Acute Myeloid Leukemia With Variant MLL Translocations / Untreated Adult Acute Myeloid Leukemia	1
2	Active Not Recruiting	Treatment	Brain and Central Nervous System Tumors	1
2	Active Not Recruiting	Treatment	CHILD B / Hepatocellular,Carcinoma	1
2	Active Not Recruiting	Treatment	Cancer, Breast	2
2	Active Not Recruiting	Treatment	Clear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer	1
2	Active Not Recruiting	Treatment	Desmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	1
2	Active Not Recruiting	Treatment	Differentiated Thyroid Cancer (DTC)	1
2	Active Not Recruiting	Treatment	Gastrointestinal Stromal Tumors	1
2	Active Not Recruiting	Treatment	HCC	1
2	Active Not Recruiting	Treatment	Head and Neck Carcinoma / Squamous Cell Carcinoma (SCC)	1
2	Active Not Recruiting	Treatment	Hepatocellular Cancer	1
2	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma	5
2	Active Not Recruiting	Treatment	Liver Cancer	2
2	Active Not Recruiting	Treatment	Lung Cancers	1
2	Active Not Recruiting	Treatment	Metastatic Colorectal Cancers	1
2	Active Not Recruiting	Treatment	Multiple Endocrine Neoplasia / Recurrent Thyroid Gland Carcinoma / Thyroid Gland Medullary Carcinoma	1
2	Active Not Recruiting	Treatment	Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer	1
2	Active Not Recruiting	Treatment	Renal Cell Adenocarcinoma	1
2	Active Not Recruiting	Treatment	Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
2	Active Not Recruiting	Treatment	Thyroid Cancers	1
2	Active Not Recruiting	Treatment	Uveal Melanoma	1
2	Completed	Supportive Care	Neuroendocrine Tumors	1
2	Completed	Treatment	Acute Myeloid Leukaemias (AML)	2
2	Completed	Treatment	Adenocarcinoma of the Extrahepatic Bile Duct / Adenocarcinoma of the Gallbladder / Adenocarcinoma With Squamous Metaplasia of the Gallbladder / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Squamous Cell Carcinoma of the Gallbladder / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer	1
2	Completed	Treatment	Adenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease	1
2	Completed	Treatment	Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer	1
2	Completed	Treatment	Adenocarcinoma of the Prostate	1
2	Completed	Treatment	Adenocarcinoma of the Prostate / Stage II Prostate Cancer / Stage III Prostate Cancer	1
2	Completed	Treatment	Adenocarcinomas	1
2	Completed	Treatment	Adenocarcinomas of the Gastroesophageal Junction / Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers	1
2	Completed	Treatment	Adult Angiosarcoma / Adult Epithelioid Sarcoma / Adult Leiomyosarcoma / Adult Malignant Fibrous Histiocytoma / Adult Neurofibrosarcoma / Adult Synovial Sarcoma / Ovarian Sarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Uterine Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage III Uterine Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Stage IV Uterine Sarcoma / Uterine Carcinosarcoma / Uterine Leiomyosarcoma	1
2	Completed	Treatment	Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor	1
2	Completed	Treatment	Advanced Hepatocellular Carcinoma / Hepatic neoplasms malignant / Liver Cancer / Neoplasms, Hepatic	1
2	Completed	Treatment	Advanced Hepatocellular Carcinoma / Inoperable Hepatocellular Carcinoma	1
2	Completed	Treatment	Advanced Renal Cell Carcinoma	1
2	Completed	Treatment	Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)	1
2	Completed	Treatment	Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma	1
2	Completed	Treatment	Anaplastic Large Cell Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma	1
2	Completed	Treatment	Bladder Cancers	1
2	Completed	Treatment	Cancer, Breast	2
2	Completed	Treatment	Cancer, Breast / Neoplasms, Breast	1
2	Completed	Treatment	Cancer, Ovarian	2
2	Completed	Treatment	Cancers / Melanoma	1
2	Completed	Treatment	Cancers / Non-Small Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	Childhood Hepatocellular Carcinoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Rhabdomyosarcoma / Recurrent Thyroid Cancer / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Thyroid Papillary Carcinoma	1
2	Completed	Treatment	Chronic Myelogenous Leukemia (CML)	1
2	Completed	Treatment	Ciliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Metastatic Intraocular Melanoma / Recurrent Intraocular Melanoma	1
2	Completed	Treatment	Clear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
2	Completed	Treatment	Clear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer	1
2	Completed	Treatment	Clinically Significant Portal Hypertension	1
2	Completed	Treatment	Colorectal Cancers	1
2	Completed	Treatment	Effects of Chemotherapy / Malignant Neoplasm of Stomach	1
2	Completed	Treatment	Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma / Stage IA Malignant Mesothelioma / Stage IB Malignant Mesothelioma / Stage II Malignant Mesothelioma / Stage III Malignant Mesothelioma / Stage IV Malignant Mesothelioma	1
2	Completed	Treatment	Esophageal Cancers / Malignant Neoplasm of Stomach	1
2	Completed	Treatment	Extensive Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer	1
2	Completed	Treatment	Extrahepatic Bile Duct Adenocarcinoma / Gallbladder Adenocarcinoma / Gallbladder Adenocarcinoma With Squamous Metaplasia / Hilar Cholangiocarcinoma / Recurrent Extrahepatic Bile Duct Carcinoma / Recurrent Gallbladder Carcinoma / Undifferentiated Gallbladder Carcinoma / Unresectable Extrahepatic Bile Duct Carcinoma / Unresectable Gallbladder Carcinoma	1
2	Completed	Treatment	Extrahepatic Bile Duct Cancer / Gallbladder Cancer	1
2	Completed	Treatment	Fallopian Tube Cancer / Neoplasms, Ovarian / Primary Peritoneal Cancer	1
2	Completed	Treatment	Gastrinoma / Glucagonoma / Insulinoma / Metastatic Gastrointestinal Carcinoid Tumor / Neuroendocrine Tumors / Pancreatic Polypeptide Tumor / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma / WDHA Syndrome	1
2	Completed	Treatment	Gastrointestinal Stromal Tumors	1
2	Completed	Treatment	Glioblastoma Multiforme	1
2	Completed	Treatment	Hepatocellular,Carcinoma	14
2	Completed	Treatment	Kidney Diseases / Renal Cancers / Renal Cell Adenocarcinoma	1
2	Completed	Treatment	Leiomyosarcomas / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas / Synovial Sarcoma	1
2	Completed	Treatment	Liver Cancer	2
2	Completed	Treatment	Lung Cancers	4
2	Completed	Treatment	Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer	1
2	Completed	Treatment	Malignant Melanoma	2
2	Completed	Treatment	Malignant Neoplasm of Pancreas	2
2	Completed	Treatment	Malignant Neoplasm of Prostate	3
2	Completed	Treatment	Melanoma	2
2	Completed	Treatment	Melanoma Stage III or IV / No Prior Chemotherapy	1
2	Completed	Treatment	Metastasis / Neoplasms	1
2	Completed	Treatment	Metastatic Anaplastic Thyroid Cancer / Metastatic Differentiated Thyroid Cancer / Metastatic Medullary Thyroid Cancer / Metastatic Poorly Differentiated Thyroid Cancer	1
2	Completed	Treatment	Metastatic Breast Cancer (MBC)	1
2	Completed	Treatment	Metastatic Cancers / Renal Cancers	1
2	Completed	Treatment	Metastatic Colorectal Cancers	1
2	Completed	Treatment	Metastatic Disease / Renal Cell Adenocarcinoma	2
2	Completed	Treatment	Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Osteosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Osteosarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma	1
2	Completed	Treatment	Metastatic Osteosarcoma / Relapsed Osteosarcoma	1
2	Completed	Treatment	Metastatic Renal Cell Carcinoma	1
2	Completed	Treatment	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary	2
2	Completed	Treatment	Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder	1
2	Completed	Treatment	Neoplasms, Head and Neck	1
2	Completed	Treatment	Neoplasms, Ovarian	1
2	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	5
2	Completed	Treatment	Primary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma	1
2	Completed	Treatment	Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma	1
2	Completed	Treatment	Recurrent Glioblastoma Multiforme	1
2	Completed	Treatment	Recurrent Melanoma / Stage IV Melanoma	1
2	Completed	Treatment	Recurrent Melanoma / Stage IV Skin Melanoma / Stages III Skin Melanoma	1
2	Completed	Treatment	Recurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer	1
2	Completed	Treatment	Recurrent Uterine Sarcoma / Stage III Uterine Sarcoma / Stage IV Uterine Sarcoma / Uterine Carcinosarcoma	1
2	Completed	Treatment	Refractory Multiple Myeloma	1
2	Completed	Treatment	Renal Cancers	1
2	Completed	Treatment	Renal Cell Adenocarcinoma	7
2	Completed	Treatment	Sarcoma, Osteogenic	1
2	Completed	Treatment	Sarcomas	1
2	Completed	Treatment	Soft Tissue Sarcoma (STS)	1
2	Completed	Treatment	Stage III Melanoma / Stage IV Melanoma	1
2	Completed	Treatment	Stage IV Pancreatic Cancer	1
2	Completed	Treatment	Thyroid Cancers	1
2	Completed	Treatment	Thyroid Carcinoma	1
2	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	1
2	Not Yet Recruiting	Treatment	Hepatocellular Cancer	1
2	Not Yet Recruiting	Treatment	Hepatocellular,Carcinoma	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia	1
2	Recruiting	Treatment	Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes	1
2	Recruiting	Treatment	Adult Primary Hepatocellular Carcinoma / Localized Resectable Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer	1
2	Recruiting	Treatment	Brain and Nervous System / Glioblastomas / Gliomas / Recurrent Adult Brain Neoplasm	1
2	Recruiting	Treatment	Cancer, Breast / Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer	1
2	Recruiting	Treatment	Cholangiocarcinoma of the Extrahepatic Bile Duct / Gallbladder Cancer	1
2	Recruiting	Treatment	Hepatocellular Cancer	1
2	Recruiting	Treatment	Hepatocellular Carcinoma (HCC)	1
2	Recruiting	Treatment	Hepatocellular,Carcinoma	2
2	Recruiting	Treatment	Hepatocellular,Carcinoma / Portal Vein Thrombosis	1
2	Recruiting	Treatment	Hepatocellular,Carcinoma / Secondary	1
2	Recruiting	Treatment	Hepatopulmonary Syndrome	1
2	Recruiting	Treatment	Leukemias	1
2	Recruiting	Treatment	Malignant Solid Neoplasms	1
2	Recruiting	Treatment	Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors	1
2	Recruiting	Treatment	Metastatic Renal Cell Carcinoma	2
2	Recruiting	Treatment	Pediatric Solid Tumors	1
2	Recruiting	Treatment	Refractory Hurthle Cell Thyroid Cancer	1
2	Recruiting	Treatment	Refractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors	1
2	Recruiting	Treatment	Renal Cell Adenocarcinoma	1
2	Recruiting	Treatment	Rhabdomyosarcomas	1
2	Recruiting	Treatment	Stage IIB Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma	1
2	Recruiting	Treatment	Thyroid Cancers	1
2	Terminated	Treatment	Adenocarcinoma of the Bladder / Distal Urethral Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Squamous Cell Carcinoma of the Bladder / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer	1
2	Terminated	Treatment	Advanced Hepatocellular Carcinoma	1
2	Terminated	Treatment	Anaplastic Thyroid Cancers / Insular Thyroid Cancer / Recurrent Thyroid Cancer / Stage III Follicular Thyroid Cancer / Stage III Papillary Thyroid Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Papillary Thyroid Cancer	1
2	Terminated	Treatment	Anaplastic Thyroid Cancers / Recurrent Thyroid Cancer	1
2	Terminated	Treatment	Bladder Cancers	1
2	Terminated	Treatment	Cancer, Breast	5
2	Terminated	Treatment	Cancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer	1
2	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
2	Terminated	Treatment	Clear Cell Renal Cell Carcinoma / Papillary Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
2	Terminated	Treatment	Clear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer	1
2	Terminated	Treatment	Hepatocellular,Carcinoma	5
2	Terminated	Treatment	Keloid Scars	1
2	Terminated	Treatment	Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Liver Cancer	1
2	Terminated	Treatment	Lung Cancer Small Cell Lung Cancer (SCLC)	1
2	Terminated	Treatment	Lung Cancers	2
2	Terminated	Treatment	Malignant Neoplasm of Stomach	1
2	Terminated	Treatment	Metastatic Breast Cancer (MBC)	1
2	Terminated	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
2	Terminated	Treatment	Metastatic Renal Cell Carcinoma	2
2	Terminated	Treatment	Neoplasms, Colorectal	1
2	Terminated	Treatment	Non Squamous Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Terminated	Treatment	Neurofibromatosis1 (NF1) / Recurrent or Progressive Low-grade Glioma / Recurrent or Progressive Optic Pathway Gliomas (OPG)	1
2	Terminated	Treatment	Refractory Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia	1
2	Terminated	Treatment	Renal Cancers	1
2	Terminated	Treatment	Renal Cell Adenocarcinoma	3
2	Terminated	Treatment	Sarcomas	1
2	Unknown Status	Diagnostic	Salivary Gland Cancers	1
2	Unknown Status	Treatment	Adrenocortical Carcinoma	1
2	Unknown Status	Treatment	Bladder Cancers	1
2	Unknown Status	Treatment	Cancer, Breast	1
2	Unknown Status	Treatment	Hepatocellular,Carcinoma	5
2	Unknown Status	Treatment	Hepatocellular,Carcinoma / Metastasis	1
2	Unknown Status	Treatment	Liver Cancer	2
2	Unknown Status	Treatment	Lung Cancers	1
2	Unknown Status	Treatment	Malignant Neoplasm of Prostate	1
2	Unknown Status	Treatment	Melanoma (Skin)	2
2	Unknown Status	Treatment	Mesothelioma	1
2	Unknown Status	Treatment	Metastatic Renal Cell Carcinoma	1
2	Unknown Status	Treatment	Neoplasms, Colorectal	1
2	Unknown Status	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Unknown Status	Treatment	Renal Cell Adenocarcinoma	2
2	Unknown Status	Treatment	Sarcomas	1
2	Unknown Status	Treatment	Testicular Cancer	1
2	Withdrawn	Treatment	Glioblastomas / Gliosarcoma	1
2	Withdrawn	Treatment	Hepatocellular,Carcinoma	1
2	Withdrawn	Treatment	Locally Metastatic Malignant Neoplasm	1
2	Withdrawn	Treatment	Lung Cancers	1
2	Withdrawn	Treatment	Malignant Neoplasm of Prostate	1
2	Withdrawn	Treatment	Medullary Thyroid Cancer (MTC)	1
2	Withdrawn	Treatment	Melanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma	1
2, 3	Recruiting	Treatment	HCC	1
2, 3	Recruiting	Treatment	Hepatocellular,Carcinoma	2
2, 3	Recruiting	Treatment	Liver Cancer	1
2, 3	Unknown Status	Treatment	Quality of Life	1
3	Active Not Recruiting	Treatment	Adult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma / BCLC Stage D Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma	1
3	Active Not Recruiting	Treatment	Cancer, Breast	1
3	Active Not Recruiting	Treatment	Desmoid-Type Fibromatosis	1
3	Active Not Recruiting	Treatment	Hepatocellular Carcinoma (HCC)	1
3	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma	3
3	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma / Non-Resectable Hepatocellular Carcinoma	1
3	Active Not Recruiting	Treatment	Neoplasms, Kidney	1
3	Active Not Recruiting	Treatment	Neoplasms, Thyroid	1
3	Completed	Treatment	Advanced Renal Cell Carcinoma	2
3	Completed	Treatment	Carcinoma NOS / Non-Small-Cell Lung	1
3	Completed	Treatment	Child-Pugh A Hepatocellular Carcinoma	1
3	Completed	Treatment	Clear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer / Stage II Renal Cell Cancer / Stage III Renal Cell Cancer	1
3	Completed	Treatment	Hepato Cellular Carcinoma (HCC)	1
3	Completed	Treatment	Hepatocellular,Carcinoma	5
3	Completed	Treatment	Liver Cancer	1
3	Completed	Treatment	Melanoma	1
3	Completed	Treatment	Metastatic Renal Cell Carcinoma	2
3	Completed	Treatment	Mucosal Melanoma / Recurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma	1
3	Completed	Treatment	Neoplasms, Kidney	1
3	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Completed	Treatment	Renal Cancers	1
3	Completed	Treatment	Renal Cell Adenocarcinoma	8
3	Not Yet Recruiting	Treatment	Hepatoblastomas / Hepatocellular,Carcinoma	1
3	Not Yet Recruiting	Treatment	Hepatocellular,Carcinoma	1
3	Recruiting	Treatment	Adult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer	1
3	Recruiting	Treatment	Granulocytic Sarcoma / Leukaemia cutis / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm	1
3	Recruiting	Treatment	HCC	1
3	Recruiting	Treatment	Hepatocellular Carcinoma (HCC)	1
3	Recruiting	Treatment	Hepatocellular,Carcinoma	1
3	Recruiting	Treatment	Hepatocellular,Carcinoma / I.V Advanced Cancer	1
3	Recruiting	Treatment	Hepatocellular,Carcinoma / Recurrences	1
3	Recruiting	Treatment	Neoplasms	1
3	Recruiting	Treatment	Renal Cell Adenocarcinoma	1
3	Terminated	Treatment	Adenocarcinomas / Carcinoma NOS / Digestive System Diseases / Digestive System Neoplasms / Hepatocellular Carcinoma Non-resectable / Hepatocellular Carcinoma Recurrent / Hepatocellular,Carcinoma / Liver Diseases / Neoplasms / Neoplasms by Histologic Type / Neoplasms by Site / Neoplasms, Glandular and Epithelial / Neoplasms, Hepatic	1
3	Terminated	Treatment	Advanced Adult Hepatocellular Carcinoma	1
3	Terminated	Treatment	Hepatocellular,Carcinoma	1
3	Terminated	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
3	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Unknown Status	Treatment	Advanced Hepatocellular Carcinoma / Carcinoma NOS / Hepatocellular,Carcinoma / Neoplasms / Neoplasms, Hepatic	1
3	Unknown Status	Treatment	Liver Cancer	1
3	Unknown Status	Treatment	Malignant Neoplasm of Pancreas	1
3	Withdrawn	Treatment	Hepatic neoplasms malignant	1
4	Completed	Not Available	Renal Cell Adenocarcinoma	1
4	Completed	Treatment	Hepatocellular,Carcinoma	2
4	Recruiting	Basic Science	Hepatocellular,Carcinoma	1
4	Recruiting	Prevention	Portal Vein Tumor Thrombus	1
4	Recruiting	Treatment	Acute Myeloid Leukaemias (AML) / Hematopoietic Stem Cell Transplantation (HSCT)	1
4	Recruiting	Treatment	Hepatectomy / Hepatocellular,Carcinoma / Sorafenib	1
4	Recruiting	Treatment	Hepatocellular,Carcinoma	1
4	Unknown Status	Treatment	Hepatocellular Cancer	1
4	Withdrawn	Not Available	Renal Cell Adenocarcinoma	1
Not Available	Active Not Recruiting	Not Available	Hepatocellular,Carcinoma	2
Not Available	Active Not Recruiting	Not Available	Renal Cell Adenocarcinoma	1
Not Available	Active Not Recruiting	Diagnostic	Advanced Solid Tumors / Cancers	1
Not Available	Active Not Recruiting	Treatment	Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia With FLT3/ITD Mutation / Adult Acute Myeloid Leukemia in Remission	1
Not Available	Active Not Recruiting	Treatment	Advanced Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Hepatocellular Carcinoma / Stage III Childhood Hepatocellular Carcinoma / Stage IIIA Hepatocellular Carcinoma / Stage IIIB Hepatocellular Carcinoma / Stage IIIC Hepatocellular Carcinoma / Stage IV Childhood Hepatocellular Carcinoma / Stage IVA Hepatocellular Carcinoma / Stage IVB Hepatocellular Carcinoma	1
Not Available	Active Not Recruiting	Treatment	Hepatocellular,Carcinoma / Liver Cell Carcinoma	1
Not Available	Active Not Recruiting	Treatment	Recurrent Childhood Brain Tumor	1
Not Available	Active Not Recruiting	Treatment	Refractory Solid Tumors	1
Not Available	Completed	Not Available	Carcinoma, Renal Cell (Advanced) / Renal Cell Adenocarcinoma	2
Not Available	Completed	Not Available	Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies	1
Not Available	Completed	Not Available	Hepatocellular,Carcinoma	6
Not Available	Completed	Not Available	Hepatocellular,Carcinoma / Renal Cell Adenocarcinoma	1
Not Available	Completed	Not Available	Renal Cell Adenocarcinoma	7
Not Available	Completed	Basic Science	Clear Cell Renal Cell Carcinoma	1
Not Available	Completed	Treatment	Cancer, Breast	1
Not Available	Completed	Treatment	Refractory Solid Tumors	1
Not Available	Not Yet Recruiting	Treatment	HCC	1
Not Available	Recruiting	Not Available	Hepatocellular,Carcinoma / Neuroendocrine Tumors	1
Not Available	Recruiting	Not Available	Neoplasms, Thyroid	1
Not Available	Recruiting	Not Available	Thyroid Carcinoma	1
Not Available	Recruiting	Treatment	Hepatocellular,Carcinoma	5
Not Available	Terminated	Not Available	Colorectal Cancers / Hepatocellular Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma	1
Not Available	Terminated	Treatment	Esophageal Cancers	1
Not Available	Terminated	Treatment	Hepatocellular,Carcinoma / Liver Cancer	1
Not Available	Terminated	Treatment	Hereditary Clear Cell Renal Cell Carcinoma / Renal Cancers	1
Not Available	Terminated	Treatment	Leptomeningeal Metastases	1
Not Available	Unknown Status	Not Available	Liver Cancer / Renal Cancers	1

Pharmacoeconomics

Manufacturers

Bayer healthcare pharmaceuticals inc

Packagers

Bayer Healthcare

Dosage forms

Form	Route	Strength
Tablet	Oral	200 mg
Tablet, film coated	Oral	200 mg/1
Tablet, film coated	Oral	200 mg

Prices

Unit description	Cost	Unit
Nexavar 200 mg tablet	66.61USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2315715	No	2010-06-22	2018-12-22	Canada
CA2359510	No	2007-02-13	2020-01-12	Canada
US7235576	No	2000-01-12	2020-01-12	US
US7351834	No	2000-01-12	2020-01-12	US
US7897623	No	2000-01-12	2020-01-12	US
US8124630	No	2000-01-12	2020-01-12	US
US8618141	No	2003-02-11	2023-02-11	US
US8841330	No	2000-01-12	2020-01-12	US
US8877933	No	2007-12-24	2027-12-24	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Insoluble	FDA label
logP	3.8	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00171 mg/mL	ALOGPS
logP	4.12	ALOGPS
logP	4.34	ChemAxon
logS	-5.4	ALOGPS
pKa (Strongest Acidic)	11.55	ChemAxon
pKa (Strongest Basic)	2.03	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	92.35 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	114.52 m³·mol^-1	ChemAxon
Polarizability	41.11 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9649
Blood Brain Barrier	+	0.851
Caco-2 permeable	-	0.5138
P-glycoprotein substrate	Non-substrate	0.5086
P-glycoprotein inhibitor I	Non-inhibitor	0.7141
P-glycoprotein inhibitor II	Non-inhibitor	0.9359
Renal organic cation transporter	Non-inhibitor	0.8938
CYP450 2C9 substrate	Non-substrate	0.6569
CYP450 2D6 substrate	Non-substrate	0.8212
CYP450 3A4 substrate	Non-substrate	0.5341
CYP450 1A2 substrate	Inhibitor	0.6168
CYP450 2C9 inhibitor	Non-inhibitor	0.6171
CYP450 2D6 inhibitor	Non-inhibitor	0.9145
CYP450 2C19 inhibitor	Inhibitor	0.637
CYP450 3A4 inhibitor	Non-inhibitor	0.7339
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.6629
Ames test	Non AMES toxic	0.8143
Carcinogenicity	Non-carcinogens	0.8684
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.7885 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9488
hERG inhibition (predictor II)	Non-inhibitor	0.6415

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.

Kingdom

Organic compounds

Super Class

Organic oxygen compounds

Class

Organooxygen compounds

Sub Class

Ethers

Direct Parent

Diarylethers

Alternative Parents

Trifluoromethylbenzenes / N-phenylureas / Pyridinecarboxamides / 2-heteroaryl carboxamides / Phenoxy compounds / Phenol ethers / Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds / Secondary carboxylic acid amides

Substituents

Diaryl ether / N-phenylurea / Trifluoromethylbenzene / Pyridinecarboxamide / Pyridine carboxylic acid or derivatives / Phenoxy compound / 2-heteroaryl carboxamide / Phenol ether / Halobenzene / Chlorobenzene

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

aromatic ether, ureas, monochlorobenzenes, (trifluoromethyl)benzenes, pyridinecarboxamide (CHEBI:50924 )

Get DrugBank to go!

Structure for DB00398 (Sorafenib)

Targets

References

References

References

References

References

References

References

References

References

References

Enzymes

References

References

References

References

References

References

References

References

References

References

Transporters

References

References

References

References

References